2022-09-29-世界卫生组织-A_H1_variant_-_Southern_hemisphere_2023_2页_177kb

Summary of Development and Availability of Variant Influenza A(H1) Candidate Vaccine Viruses

The World Health Organization's Global Influenza Surveillance and Response System (GISRS) conducts antigenic and genetic analyses for candidate vaccine viruses, which are developed to address variant influenza A(H1). These viruses have undergone relevant safety testing and can be handled under BSL-2 enhanced containment.

Key details:

• Approved candidate vaccine viruses, such as those based on A/Ohio/24/2017 (H1N2)v and A/Ohio/9/2015 (H1N1)v, have passed two-way haemagglutination inhibition (HI) tests and are available for use upon approval by national or regional control authorities.
• Institutes involved include CDC (USA), WHO Collaborating Centres, CNIC-CCDC (China), and others.
• Several viruses are in preparation or pending status, awaiting further development or approval, with details from sources like SJCRH, NIBSC, and WHO CCs.
• Contact information for orders and inquiries is provided via specific institute emails and the WHO for additional resources on potency testing reagents.

For full details, refer to the referenced WHO links.